INTRODUCTION
Depression and anxiety are known to be prevalent in patients with cancer, but rates of post-traumatic stress disorder (PTSD) have been examined less frequently in this population. Despite the identification of cancer as a potential trauma in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 1 PTSD in patients with cancer remains a relatively new field of research. 2 Cancer diagnosis and treatment are unique, long-term traumatic stressors, as first described by PTSD field trials for the DSM-IV. 1 The concept of cancer as an enduring risk is important given the potential for disease relapse and progression. [3] [4] [5] PTSD is an especially pertinent issue in cancer given its association with maladaptive patterns of avoidance behavior, which may increase the likelihood of nonadherence with cancer surveillance or treatment and poorer cancer outcomes. 6 There is limited knowledge about how the rates of PTSD and other psychiatric disorders among patients with cancer may differ according to nation, region, and culture. [7] [8] [9] Findings from the BQUAL study, 7 which focused on symptoms of PTSD among oncology patients up to 6 months after their initial cancer diagnosis, suggest that Asian patients with cancer may be at greater risk of PTSD symptoms compared with patients of Caucasian descent.
Worldwide, studies of PTSD in patients with cancer have reported incidence rates ranging from 0% to 6% when diagnostic structured clinical interviews are used. [10] [11] [12] Only 6 existing studies of 100 or more patients, mainly conducted among women with breast and gynecologic cancers [12] [13] [14] [15] [16] but also among bone marrow transplantation recipients 17 (range, 102-506 patients), have reported the prevalence of PTSD using a validated diagnostic interview. Of those studies, only Voigt et al 13 examined PTSD with a longitudinal design using repeated clinical assessments over the course of 1 year and observed that more than one-half of patients displayed 1 or more PTSD symptoms at 1 year after the cancer diagnosis.
To the best of our knowledge, there are no studies examining PTSD in patients with cancer that have used gold-standard clinical interviews and followed a cohort for a period as long as 4 years. The objective of our current study was to assess the course and predictors of PTSD in adult patients with cancer over a 4-year period in a SouthEast Asian population. We hypothesized that the presence of psychological distress at diagnosis and after treatment would predict PTSD, and that PTSD would persist in the long term for a small proportion of the sample.
MATERIALS AND METHODS
A prospective cohort study was conducted at a single academic medical center among consecutive patients who were newly diagnosed with cancer and were approached within 1 month of diagnosis for a face-to-face interview. This study is part of a larger longitudinal cohort study examining psychological issues in cancer. For further details of the cohort, please refer to the previous published report. 18 In the current study, we mainly focused on the natural course of psychological distress and PTSD among adult patients with cancer from diagnosis until a 4-year follow-up assessment. All adult patients at the medical center who were newly diagnosed with cancer were consecutively enrolled and formed the basis of the original cohort. An updated Consolidated Standards of Reporting Trials (CONSORT) diagram (Fig. 1 ) based on the original study cohort 18 details the latest information from the current study.
Inclusion criteria were: 1) any type of cancer, 2) ability to complete the battery of necessary interviews and questionnaires, and 3) ability to understand the objective of the study and provide informed consent. Patients who were not aware of their cancer diagnosis and those who were too ill to tolerate an interview were excluded from participating.
The purpose and details of the study were explained to all potential patients, and participants who provided written informed consent were enrolled. This study was approved by the Institutional Review Board of the medical center; a description of eligibility and accrual procedures is available elsewhere. 18 The Hospital Anxiety and Depression Scale (HADS) was administered at baseline, from 4 to 6 weeks later, at a 1-year follow-up assessment, and at a 4-year follow-up assessment. The Structured Clinical Interview for DSM-IV Axis I disorders/nonpatient edition (SCID-I/NP) module for PTSD was administered to patients with cancer who had elevated HADS scores at the 6-month follow-up assessment, whereas all patients underwent the SCID at 4-year follow-up. Telephone interviews were conducted if patients were unable to attend or complete follow-up interviews. All assessments were conducted on a 1-to-1 basis by psychologists trained in the administration of the SCID module.
Written informed consent was obtained from all participants. To ensure anonymity and confidentiality, all successfully enrolled patients were assigned and tracked using a progressive participant number. Patient medical notes were retrieved to verify information obtained from patient interviews, such as cancer type and cancer stage. Survival status was extracted from the hospital registry database and confirmed through the National Death Registry.
Measures
Two main instruments were used in the study to measure the following:
Psychological distress
The HADS 19 is the most frequently reported measure of psychological distress in cancer studies. Preliminary testing for the English-language HADS yielded a Cronbach a of 0.91. 20 The Malay version of the HADS has been used in previous large cohort studies in Malaysian patients with cancer 21 and has demonstrated excellent internal consistency with Cronbach a values of 0.88 for the anxiety subscale and 0.79 for the depression subscale. 22 The anxiety and depression subscales on the HADS are 7-item subscales scored on a 4-point Likert scale (from 0 to 3; with higher scores indicate more distress), yielding maximum subscale scores of 21 for anxiety and depression, respectively, and a maximum total score of 42. We used a cutoff score 8 on each individual subscale or 16 for the total HADS score to indicate significant psychological distress. 23, 24 Significant psychological distress at baseline and a 4-week to 6-week follow-up assessment was used to determine the need for further assessment using the SCID.
PTSD diagnoses
Structured clinical interviews are the diagnostic goldstandard in psychiatric research. 25 The SCID-I/NP based on the DSM-IV-TR 26 was used to assess current PTSD at 6-months follow-up (in patients who indicated elevated psychological distress at baseline and/or at 4-6 weeks of follow-up) and at 4-years follow-up (for all patients regardless of their initial HADS scores). As the data were collected before DSM-5, the focus of the study was on PTSD symptoms specified in the DSM-IV-TR. 27 We assessed inter-rater reliability using double rating of 50 clinical interviews (SCIDs) by a second trained psychologist. Overall agreement on whether a PTSD diagnosis should be assigned was excellent at 96%. Time to complete the interview ranged from 30 to 50 minutes.
Cancer was predefined as the potentially traumatic event patients should discuss when administered the SCID. To establish a PTSD diagnosis, criteria according to the DSM-IV-TR had to be met as follows: a patient 
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Cancer had to meet criterion A (traumatic exposure and response) and to report at least 1 re-experiencing symptom (criterion B), 3 avoidance/numbing symptoms (criterion C), and 2 arousal symptoms (criterion D) for more than 1 month (criterion E) with significant distress or functional impairment (criterion F). 26 We used the following definition for subsyndromal PTSD: Criteria A (traumatic exposure and response), F (distress or functional impairment), and E (duration) had to be met, along with the presence of a minimum of 6 PTSD symptoms from at least 3 of the following 4 criteria: Criteria B (re-experiencing), C (avoidance/numbing), D (hyperarousal), and E (duration). No particular criteria set was used to allow for multiple ways of addressing partial symptoms.
Our objective in allowing a flexible definition was to identify patients with subsyndromal PTSD in cases where not all symptoms met the 1-month duration or no symptom from a particular criterion was met, despite the presence of multiple symptoms from other criteria. Our subsyndromal definition follows an approach similar to the definition used by Franklin and colleagues, 28 which requires the presence of the same number of symptoms as full PTSD. Our approach also requires that symptoms include at least 3 of 4 criteria (criteria B, C, D, and E). This is an adaptation of the more conservative subsyndromal PTSD criteria used by Blanchard et al, 29 which stipulates that at least 2 criteria be met (criteria B and C or criteria B and D).
In all, there were 4 distinct groups of patients: The PTSD group met full DSM-IV-TR criteria, the subsyndromal PTSD group partially met DSM-IV-TR criteria, the "no PTSD" group did not meet criteria even for subsyndromal PTSD, and the "nonprobable PTSD" group did not undergo the SCID at the 6-month follow-up, because they were excluded from clinical interview on the basis of low psychological distress.
Statistical Analysis
The chi-square test was used to determine differences in terms of sociodemographic characteristics between patients with and without PTSD. Statistical comparisons were 2-sided, using P < .05 as the level of significance. A repeated-measures analysis of variance (ANOVA) was conducted to examine the effect of psychological distress, as assessed at baseline and at 4 to 6 weeks, 1-year, and 4-years, on PTSD at the 6-month and 4-year follow-up assessments. Repeated HADS measurements precluded the inclusion of psychological distress because of multicollinearity. Thus we chose to analyze psychological distress separately using a repeated-measures ANOVA rather than a regression. A separate binary logistic regression was used to test for predictors of PTSD at 6-months and 4-years follow-up. We used all available data without imputations for missing data. All analyses were performed using the Statistical Package for the Social Sciences software package (SPSS version 20; IBM Corporation, Armonk, NY). 30 
RESULTS
Baseline demographic, clinical, and psychosocial characteristics of the 439 individuals who completed both the HADS and the PTSD assessments from the original cohort of 469 study participants are provided in Table 1 according to PTSD status. At the 6-month follow-up assessment, 203 of 222 patients with elevated HADS scores underwent the structured clinical interview. In total, 210 deaths occurred during the study period; and, of the remaining 247 patients at the 4-years follow-up assessment, 245 patients were successfully re-interviewed (2 patients were lost to follow-up).
The SCID interviews were used to classify patients based on current symptoms at the 6-month follow-up assessment according to the following categories: PTSD diagnosis (n 5 27), subsyndromal PTSD (n 5 17), no PTSD (n 5 159) and nonprobable PTSD (n 5 236). The "no PTSD" category refers to patients who did not meet criteria even for a subsyndromal PTSD diagnosis. The nonprobable PTSD group did not undergo the SCID at the 6-months follow-up assessment because they were excluded on the basis of low psychological distress. All patients underwent the SCID at the 4-year follow-up assessment.
When comparisons were made across the PTSD, subsyndromal, no PTSD and nonprobable PTSD groups, patients did not appear to differ from each other significantly in terms of their sex, age at diagnosis, ethnicity, or marital status. However, chi-square tests revealed a significant difference in terms of cancer type and stage, performance status, education level, and employment status. An examination of standardized residuals did not reveal any cells with a value outside of 61. We also entered the characteristics that were flagged as significant (using chisquare tests) into the logistic regression as covariates for further analyses.
At the 6-month follow-up, 27 of 203 patients (13.3%) met the full criteria for PTSD, and another 17 patients (8.4%) had subsyndromal PTSD symptoms. This yielded a 21.7% PTSD incidence when patients with both full and subsyndromal PTSD were aggregated. At the 4-year follow-up, 10 of 245 patients (4.1%) had full PTSD, and 5 (2%) had subsyndromal PTSD. When patients with both full and subsyndromal PTSD were combined, this yielded a 6.1% incidence. Item-by-item frequency and percentages of endorsed PTSD criteria for the 6-month and 4-year follow-up assessments are listed in full detail in Table 2 .
Of the 27 patients who were initially diagnosed with full PTSD at the 6-month follow-up, 6 patients (22.2%) had full PTSD at the 4-year follow-up; whereas, of the remaining patients, 3 (11.1%) had no PTSD, 2 (7.4%) had subsyndromal PTSD, 1 (3.7%) was lost to follow-up, and 15 (55.6%) had died. Of the 17 patients who had subsyndromal PTSD at the 6-month follow-up, 3 (17.6%) met full PTSD criteria, 4 (23.5%) had no PTSD, and 10 (58.8%) had died by the 4-year follow-up.
Overall, 15 of 44 (34.1%) patients with cancer who were initially diagnosed with full or subsyndromal PTSD at 6-months went on to develop full PTSD at 4-years. None of the patients from the no PTSD group at 6-months had PTSD at 4-years follow-up.
Psychological distress, as measured using total HADS scores at baseline, 4 to 6 weeks, 1 year, and 4 years, is depicted by PTSD status at the 6-month (Fig. 2) and 4-year (Fig. 3) follow-up assessments.
A repeated-measures ANOVA was conducted to examine the effect of HADS, as measured at baseline, 4 to 6 weeks, 1 year, and 4 years (entered as withinsubject or independent variables), on PTSD at the 6-month and 4-year follow-up assessments (between-subject factors or dependent variables). On the basis of the repeated-measures ANOVA, the Mauchly test of sphericity indicated that the assumption of sphericity had been violated (chi-square statistic 5 25.44; P < .05); therefore, degrees of freedom were corrected using Greenhouse-Geisser estimates of sphericity (e 5 0.75). A significant main effect for psychological distress was detected (Wilks k 5 0. A binary logistic regression was run to examine the predictors of PTSD in patients with cancer. Inspection of the differences at the multivariate level using logistic regression analyses revealed that patients with breast cancer were 3.68 times less likely to develop PTSD by the 6-month follow-up assessment (odds ratio, 0.272; 95% confidence interval, 0.089-0.834). There were no significant predictors of PTSD at 4 years of follow-up (Table 3) .
DISCUSSION
This study is the first in this region to examine PTSD longitudinally at 2 different times, providing data that span a full 4 years using gold-standard clinical interviews. Our findings add to the literature on PTSD among patients with cancer, because many of the previous studies are mainly conducted by self-assessment and remain largely cross-sectional. 31 To our knowledge, this study represents 1 of the longest follow-up studies to date examining the course and predictors of PTSD among patients with cancer.
It is striking to note the high rate of PTSD in this study. Approximately 1 in 5 patients (21.7%) with cancer at the 6-month follow-up had PTSD. The prevalence rate at the 6-month follow-up in this study appears to be much higher than the prevalence estimates of 0% to 6% typically reported in studies that use clinical interviews among individuals with cancer. [10] [11] [12] There are several possible explanations for this. First, the higher rate is accounted for in part by the inclusion of patients with subsyndromal PTSD (13.3% and 8.4% for full and subsyndromal PTSD, respectively, at the 6-month followup). Also, some previous evidence 7 indicating that Asian patients with cancer are disproportionally affected by PTSD compared with Caucasians may explain the higher rate of PTSD reported in our sample. Unlike other studies that focus on patients by cancer type (eg, breast cancer), our sample comprised a cohort of patients with various cancer types and is likely to be more reflective of the true rate of PTSD in a cancer clinic. This sample also may differ from previous studies in that it focuses on a resourcelimited setting in which the psychological needs of patients with cancer are not always given adequate priority, with only the most severe cases typically receiving attention and treatment.
At the 4-year follow-up assessment, PTSD rates dropped to 6.1%. This is in line with other studies suggesting that the prevalence of PTSD declines over time. 32 At first glance, it may appear that, 4 years after a cancer diagnosis, the risk of PTSD in this highly distressed cancer population is no different from the risk for individuals who have never been diagnosed with cancer. On the basis of current evidence (all of which comes from studies outside of Asia), this is comparable to general population levels of 6.8% in the United States 33 and from 0.56% to 6.67% in Europe. 34 This finding suggests an easily overlooked reason why PTSD may be under-detected among Original Article
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Cancer patients with cancer. Such similar-to-population levels of PTSD prevalence can mask the reality that patients remain at risk of PTSD 6 months or even 4 years after their cancer diagnosis. Our data underscore the risk of developing persistent PTSD even years after cancer diagnosis and treatment. Approximately one-third (34.1%) of patients with cancer who are initially diagnosed with full or subsyndromal PTSD at 6-months went on to develop chronic or full PTSD at 4-years follow-up. This finding is fairly consistent with a non-SCID study by Smith et al, 3 in which more than one-third of long-term cancer survivors experienced persisting or worsening PTSD symptoms for more than 5 years. This highlights a need to monitor PTSD among long-term cancer survivors, especially because many of the symptoms of PTSD, such as avoidance and cognitive difficulties (as well as psychological distress), are enduring, which may potentially impact adherence to treatment. In our prior work with this cohort, the rate of treatment nonadherence or default (34%) was significant, although it was not linked to rates of psychological distress. 35 Breast cancer appeared to be a protective factor for PTSD at 6-months, but not at 4-years, follow-up. Because breast cancer is a very common malignancy, it is possible that greater societal understanding and the wider availability of support programs tailored for breast cancer (compared with the fewer support programs for patients with other cancer types) initially serve as protective factors against PTSD, but that this protective effect attenuates with distance from the original diagnosis. Overall, however, our results are consistent with past findings suggesting that cancer-specific variables, such as cancer type, cancer stage, and treatment type, are seldom significantly Original Article
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Cancer associated with PTSD symptoms in cancer survivors, as reported in the literature. 32, 36 Several limitations of our study must be acknowledged. This was a sample of patients with cancer from only 1 academic medical center. Unfortunately, we are not able to conclude definitively whether those with low baseline levels of anxiety and depression may nonetheless develop PTSD in the short term (eg, within the first year of diagnosis), because patients with low baseline psychological distress were not formally assessed for PTSD at that time point. However, it is worth noting in this context that none of the participants who had low psychological distress at baseline and/or at 4 to 6 weeks of follow-up met the criteria for PTSD at 4-years follow-up. We used DSM-IV criteria rather than DSM-5 criteria in the current study, as it was the only available option at the time of study initiation. 37 Because there is no significant change in PTSD criteria from the DSM-IV, 9,27 our current findings remain valid. Another limitation is the relatively small number of patients who had PTSD diagnosed using the SCID, because a higher prevalence would have allowed greater differentiation between the PTSD, subsyndromal PTSD, and non-PTSD groups. Because of the low number of patients with PTSD, we chose to analyze the subsyndromal and full PTSD groups together. We believe this is acceptable, because, in clinical practice, the diagnosis of PTSD is typically made through prototype, and those with subsyndromal and full PTSD are similarly managed. 38 Among the strengths of this study include the large sample size and robust response rates. Added to this was the use of a prospective, longitudinal design with data from the time of cancer diagnosis. We acknowledge that longitudinal assessments of a noncancer comparison group to provide a reference estimate of PTSD rates would have further improved the study.
The high rates of PTSD in our study indicate that Asian patients with cancer may be at higher risk of developing PTSD within the first 6 months of diagnosis and treatment rather than later on during the survivorship period. Our results underline the importance of specifically screening for PTSD in cancer survivors with high levels of psychological distress, because one-third of these patients met the criteria for PTSD at the 4-year follow-up assessment. A survivorship program that provides routine screening for PTSD, even during long-term follow-up, is recommended. In general, an innovative approach is needed to introduce psychological screening and support in this part of the world given the importance of PTSD in cancer survivorship. Cross-national research also is needed to confirm whether there are differences between Asian and Western patients with cancer in this regard. PTSD may emerge as a specific need, which, along with psychological distress, forms a substantial agenda in this underserved population.
